VILOBELIMAB
UNII F5T0RF9ZJA

Substance Identification & Data

This profile provides standardized clinical and technical data for Vilobelimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) F5T0RF9ZJA.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2250440-41-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

F5T0RF9ZJA

CAS Registry Number

2250440-41-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VILOBELIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

F5T0RF9ZJA

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C172643

National Cancer Institute reference terminology for clinical and research data.

INN ID

11304

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-123

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vilobelimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VILOBELIMAB

Common Names & Synonyms

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS C5 (COMPLEMENT 5) ANAPHYLATOXIN (C5A, C5 PR678-751)), CHIMERIC MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN CHIMERIC (1-446) (VH (MUS MUSCULUS IGHV1-61*01 (81.6%)-(IGHD)-IGHJ3*01 (92.9%)/HOMO SAPIENS IGHV1-46*01 (62.2%)-(IGHD)-IGHJ4*01 (92.9%)) (8.8.13) (1-119)-HOMO SAPIENS IGHG4*01 (CH1 (120-217), HINGE 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-446)), (133-218')-DISULFIDE WITH KAPPA LIGHT CHAIN CHIMERIC (1'-218') (V-KAPPA (MUS MUSCULUS IGKV3-4*01 (98.0%)-IGKJ2*01 (100%)/HOMO SAPIENSIGKV3D-11*02 (69.1%)-IGKJ2*01 (91.7%)) (10.3.9) (1'-111')-HOMO SAPIENSIGKC*01 (100%), KM3 A45.1 (157), V101 (195) (112'-218'))DIMER (225-225'':228-228'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA

VILOBELIMAB [INN]

VILOBELIMAB [USAN]

VILOBELIMAB [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G4, ANTI-(HUMAN COMPLEMENT C5A) (HUMAN-MUS MUSCULUS MONOCLONAL IFX-1 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL IFX-1 .KAPPA.-CHAIN, DIMER

SYS